Genome-Wide Analysis Of Differential Methylation In Pancreatic Cancer

Fan Yin,Huan Wang,Yuehua Men,Jidong Li,Minggen Hu,Qingfang Li
2016-01-01
Abstract:Pancreatic cancer as a fatal malignant tumor is difficult in diagnosis and treatment. Effective biomarkers are demanded in clinical practice. Up to now, there is little known about the DNA methylation signatures across the whole genome scale in pancreatic cancer. In this study, comparison of differential mathylation sites was performed between pancreatic cancer tissues and pericarcinous tissues using Infinium Human Methylation 450 Beadchips. A total of 24,417 CpG sites representing 9,589 genes were identified between two cohorts. Of the 24,417 CpG sites, 14,721 (60%, 14,721 of 24,417) CpG sites were hypomethylated and 9,705 (40%, 9,705 of 24,417) CpG sites were hypermethylated. GO (Gene Ontology) and KEGG analysis were implemented to systematically characterize the significant differential methylated genes between pancreatic cancer tissues and pericarcinous tissues. In addition, we further screened 51 genes with aberrant methylation, which were the most likely candidate methylation markers within the scale of global differential methylation profiling. GO and KEGG analysis indicated these genes owning a wide range of functions. The identification of differential methylated genes in this study provides information valuable to the in-depth study of pancreatic cancer.
What problem does this paper attempt to address?